3/16/2024 0 Comments Schrödinger![]() Along with using certain biomarkers to select the patient populations and tumor types that will be best served by the molecules, the researchers will also be identifying and validating biomarkers that predict response or resistance to WEE1 inhibitors. Schrödinger and MD Anderson will study their identified WEE1 inhibitor molecules as both standalone treatments and as part of combination therapies, Akinsanya said. Inhibiting the WEE1 mechanism in cancer patients, then, will maintain damage in tumor cells, potentially leading to DNA breakage and cell death rather than metastasis. The WEE1 enzyme is known as a gatekeeper, since it blocks damaged cells from replicating, giving them time to conduct DNA repair before proceeding with the cell division process. RELATED: Zai Lab to pay Schrödinger up to $338M in biobucks for oncology R&D collab ![]() “We have identified multiple highly selective WEE1 inhibitors with desirable drug-like properties that show strong pharmacodynamic responses and anti-tumor activity in preclinical models.” “We are excited to work with MD Anderson’s researchers to speed the development of our WEE1 program and potentially advance a new therapeutic option for patients,” said Karen Akinsanya, Ph.D., Schrödinger’s chief biomedical scientist and head of discovery research and development. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |